Literature DB >> 12615718

Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity.

Brian W Pogue1, Julia A O'Hara, Eugene Demidenko, Carmen M Wilmot, Isak A Goodwin, Bin Chen, Harold M Swartz, Tayyaba Hasan.   

Abstract

Photodynamic therapy (PDT) with verteporfin (lipid form of benzoporphyrin derivative,benzoporphyrin derivative monoacid ring A) was used to treat radiation-induced fibrosarcoma tumors before X-ray treatment. When verteporfin was injected 3 h before light irradiation, the tumor partial pressure of oxygen (pO(2)) rose from a pretreatment value of 2.8 +/- 1 to 15.2 +/- 6.9 mm Hg immediately after light application was complete (P = 0.048). When the optical irradiation was given 15 min after verteporfin injection, the tumor pO(2) decreased slightly after treatment [i.e., 6.8 +/- 1.6 mm Hg (pretreatment) versus 4.1 +/- 0.3 mm Hg (posttreatment)], whereas control tumor pO(2) did not change significantly. In vitro study of the cellular oxygen consumption rate before and after PDT treatment indicated that the consumption rate decreased linearly with delivered optical dose and quantitatively matched the loss of cell viability as measured by a mitochondrial tetrazolium assay. Doppler measurements show that red cell flux is still patent immediately after treatment, indicating that oxygen should still be delivered to the tumor. Computational simulations of the oxygen supply from the vessels and the consumption from mitochondrial activity confirmed that if oxygen consumption is decreased in the presence of unhindered blood flow, the tumor oxygenation should rise, and the hypoxic fraction of the tumor should decrease. Combination treatments with PDT delivered (100 J/cm(2) optical dose, with 1 mg/kg benzoporphyrin derivative monoacid ring A injected 3 h before treatment) after radiation treatment (10 Gy from 300 keV source) were compared with PDT delivered simultaneously with radiation. Tumor regrowth assay showed that the delays to reach double the tumor volume for PDT alone and radiation alone were 2.7 +/- 1.6 and 3.2 +/- 1.7 days, respectively. When radiation was given before PDT, the delay was 5.4 +/- 1.4 days, and when PDT was given at the same time as radiation, the delay was 8.1 +/- 1.5 days. This observation indicates that the combined effect in the latter case was greater than additive (P = 0.049).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615718

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  The application of physical pretreatment in photodynamic therapy for skin diseases.

Authors:  Dihui Liu; Shuang Zhao; Jinmao Li; Mingliang Chen; Lisha Wu
Journal:  Lasers Med Sci       Date:  2021-01-06       Impact factor: 3.161

Review 3.  Optical and x-ray technology synergies enabling diagnostic and therapeutic applications in medicine.

Authors:  Brian W Pogue; Brian C Wilson
Journal:  J Biomed Opt       Date:  2018-10       Impact factor: 3.170

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.

Authors:  Shannon M Gallagher-Colombo; Joann Miller; Keith A Cengel; Mary E Putt; Sergei A Vinogradov; Theresa M Busch
Journal:  Cancer Res       Date:  2015-06-08       Impact factor: 12.701

6.  Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.

Authors:  Huagang Hou; Sriram P Mupparaju; Jean P Lariviere; Sassan Hodge; Jiang Gui; Harold M Swartz; Nadeem Khan
Journal:  Radiat Res       Date:  2013-02-07       Impact factor: 2.841

7.  Rethinking cancer nanotheranostics.

Authors:  Hongmin Chen; Weizhong Zhang; Guizhi Zhu; Jin Xie; Xiaoyuan Chen
Journal:  Nat Rev Mater       Date:  2017-05-09       Impact factor: 66.308

8.  Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy.

Authors:  Huagang Hou; Jean P Lariviere; Eugene Demidenko; David Gladstone; Harold Swartz; Nadeem Khan
Journal:  Radiother Oncol       Date:  2008-11-14       Impact factor: 6.280

9.  Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.

Authors:  Chad D Cole; James K Liu; Xiaoming Sheng; Steven S Chin; Meic H Schmidt; Martin H Weiss; William T Couldwell
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

10.  Treatment of canine osseous tumors with photodynamic therapy: a pilot study.

Authors:  S Burch; C London; B Seguin; C Rodriguez; B C Wilson; S K Bisland
Journal:  Clin Orthop Relat Res       Date:  2009-01-22       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.